The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging, treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and cancer of the bile ducts (intrahepatic and extrahepatic cholangiocarcinoma). Due to the multiple modalities that can be used to treat the disease and the complications that can arise from comorbid liver dysfunction, a multidisciplinary evaluation is essential for determining an optimal treatment strategy. A multidisciplinary team should include hepatologists, diagnostic radiologists, interventional radiologists, surgeons, medical oncologists, and pathologists with hepatobiliary cancer expertise. In addition to surgery, transplant, and intra-arterial therapies, there have been great advances in the systemic treatment of HCC. Until recently, sorafenib was the only systemic therapy option for patients with advanced HCC. In 2020, the combination of atezolizumab and bevacizumab became the first regimen to show superior survival to sorafenib, gaining it FDA approval as a new frontline standard regimen for unresectable or metastatic HCC. This article discusses the NCCN Guidelines recommendations for HCC.
Individual Disclosures for the NCCN Hepatobiliary Cancers Panel
RyersonAB, EhemanCR, AltekruseSF, et al.Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer2016;122:1312–1337.
RyersonAB, EhemanCR, AltekruseSF, Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer 2016;122:1312–1337. 10.1002/cncr.29936)| false
AkinyemijuT, AberaS, AhmedM, et al.The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol2017;3:1683–1691.
AkinyemijuT, AberaS, AhmedM, The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol 2017;3:1683–1691. 10.1001/jamaoncol.2017.305528983565)| false
MarreroJA, KulikLM, SirlinCB, et al.Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases. Hepatology2018;68:723–750.
MarreroJA, KulikLM, SirlinCB, Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases. Hepatology 2018;68:723–750. 10.1002/hep.29913)| false
IslamiF, MillerKD, SiegelRL, et al.Disparities in liver cancer occurrence in the United States by race/ethnicity and state. CA Cancer J Clin2017;67:273–289.
IslamiF, MillerKD, SiegelRL, Disparities in liver cancer occurrence in the United States by race/ethnicity and state. CA Cancer J Clin 2017;67:273–289. 10.3322/caac.21402)| false
MelkonianSC, JimMA, ReilleyB, et al.Incidence of primary liver cancer in American Indians and Alaska Natives, US, 1999-2009. Cancer Causes Control2018;29:833–844.
MelkonianSC, JimMA, ReilleyB, Incidence of primary liver cancer in American Indians and Alaska Natives, US, 1999-2009. Cancer Causes Control 2018;29:833–844. 10.1007/s10552-018-1059-330030669)| false
de MartelC, Maucort-BoulchD, PlummerM, et al.World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology2015;62:1190–1200.
de MartelC, Maucort-BoulchD, PlummerM, World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology 2015;62:1190–1200. 10.1002/hep.27969)| false
SunJ, AlthoffKN, JingY, et al.Trends in hepatocellular carcinoma incidence and risk among persons with HIV in the US and Canada, 1996-2015. JAMA Netw Open2021;4:e2037512.
SunJ, AlthoffKN, JingY, Trends in hepatocellular carcinoma incidence and risk among persons with HIV in the US and Canada, 1996-2015. JAMA Netw Open 2021;4:e2037512. 10.1001/jamanetworkopen.2020.3751233595662)| false
Ganne-CarriéN, NahonP.Hepatocellular carcinoma in the setting of alcohol-related liver disease. J Hepatol 2019;70:284–293. 10.1016/j.jhep.2018.10.00830658729)| false
KanwalF, KramerJR, MapakshiS, et al.Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology2018;155:1828–1837 e1822.
KanwalF, KramerJR, MapakshiS, Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology 2018;155:1828–1837 e1822. 10.1053/j.gastro.2018.08.02430144434)| false
AschaMS, HanounehIA, LopezR, et al.The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology2010;51:1972–1978.
AschaMS, HanounehIA, LopezR, The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010;51:1972–1978. 10.1002/hep.2352720209604)| false
ElmbergM, HultcrantzR, EkbomA, et al.Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology2003;125:1733–1741.
ElmbergM, HultcrantzR, EkbomA, Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 2003;125:1733–1741. 1472482610.1053/j.gastro.2003.09.035)| false
TakamatsuS, NoguchiN, KudohA, et al.Influence of risk factors for metabolic syndrome and non-alcoholic fatty liver disease on the progression and prognosis of hepatocellular carcinoma. Hepatogastroenterology2008;55:609–614.
TakamatsuS, NoguchiN, KudohA, Influence of risk factors for metabolic syndrome and non-alcoholic fatty liver disease on the progression and prognosis of hepatocellular carcinoma. Hepatogastroenterology 2008;55:609–614.18613418)| false
NatsuizakaM, OmuraT, AkaikeT, et al.Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol2005;20:1781–1787.
HeimbachJK, KulikLM, FinnRS, AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67:358–380. 2813084610.1002/hep.29086)| false
European Association For The Study Of The LiverEuropean Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol2012;56:908–943.
European Association For The Study Of The LiverEuropean Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908–943. 22424438)| false
ZhangB-H, YangB-H, TangZ-Y.Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417–422. 1504235910.1007/s00432-004-0552-0)| false
WaidelyE, Al-YuobiAR, BashammakhAS, et al.Serum protein biomarkers relevant to hepatocellular carcinoma and their detection. Analyst (Lond)2016;141:36–44.
WaidelyE, Al-YuobiAR, BashammakhAS, Serum protein biomarkers relevant to hepatocellular carcinoma and their detection. Analyst (Lond) 2016;141:36–44. 10.1039/C5AN01884F)| false
ZhangB, YangB.Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer. J Med Screen 1999;6:108–110. 1044473110.1136/jms.6.2.108)| false
TongMJ, RosinskiAA, HuynhCT, et al.Long-term survival after surveillance and treatment in patients with chronic viral hepatitis and hepatocellular carcinoma. Hepatol Commun2017;1:595–608.
TongMJ, RosinskiAA, HuynhCT, Long-term survival after surveillance and treatment in patients with chronic viral hepatitis and hepatocellular carcinoma. Hepatol Commun 2017;1:595–608. 10.1002/hep4.104729404481)| false
International Consensus Group for Hepatocellular NeoplasiaThe International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology2009;49:658–664.
International Consensus Group for Hepatocellular NeoplasiaThe International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009;49:658–664. )| false
LokAS, SterlingRK, EverhartJE, et al.Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology2010;138:493–502.
LokAS, SterlingRK, EverhartJE, Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010;138:493–502. 1985296310.1053/j.gastro.2009.10.031)| false
TangkijvanichP, AnukulkarnkusolN, SuwangoolP, et al.Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol2000;31:302–308.
TzartzevaK, ObiJ, RichNE, et al.Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology2018;154:1706–1718.e1.
TzartzevaK, ObiJ, RichNE, Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology 2018;154:1706–1718.e1. 10.1053/j.gastro.2018.01.06429425931)| false
ArrietaO, CachoB, Morales-EspinosaD, et al.The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis. BMC Cancer2007;7:28.
ArrietaO, CachoB, Morales-EspinosaD, The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis. BMC Cancer 2007;7:28. 10.1186/1471-2407-7-28)| false
MarreroJA, HussainHK, NghiemHV, et al.Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl2005;11:281–289.
MarreroJA, HussainHK, NghiemHV, Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl 2005;11:281–289. 10.1002/lt.2035715719410)| false
MillerG, SchwartzLH, D’AngelicaM.The use of imaging in the diagnosis and staging of hepatobiliary malignancies. Surg Oncol Clin N Am 2007;16:343–368. 10.1016/j.soc.2007.04.00117560517)| false
FornerA, VilanaR, AyusoC, et al.Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology2008;47:97–104.
FornerA, VilanaR, AyusoC, Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008;47:97–104. 10.1002/hep.21966)| false
ChoiJY, LeeJM, SirlinCB.CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology2014;273:30–50.
ChoiJY, LeeJM, SirlinCB.CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology 2014;273:30–50. 10.1148/radiol.14132362)| false
TangA, BashirMR, CorwinMT, et al.Evidence supporting LI-RADS major features for CT- and MR imaging-based diagnosis of hepatocellular carcinoma: a systematic review. Radiology2018;286:29–48.
TangA, BashirMR, CorwinMT, Evidence supporting LI-RADS major features for CT- and MR imaging-based diagnosis of hepatocellular carcinoma: a systematic review. Radiology 2018;286:29–48. 10.1148/radiol.2017170554)| false
KieransAS, KangSK, RosenkrantzAB.The diagnostic performance of dynamic contrast-enhanced MR imaging for detection of small hepatocellular carcinoma measuring up to 2 cm: a meta-analysis. Radiology2016;278:82–94.
KieransAS, KangSK, RosenkrantzAB.The diagnostic performance of dynamic contrast-enhanced MR imaging for detection of small hepatocellular carcinoma measuring up to 2 cm: a meta-analysis. Radiology 2016;278:82–94. 10.1148/radiol.201515017726098460)| false
SangiovanniA, ManiniMA, IavaroneM, et al.The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut2010;59:638–644.
SangiovanniA, ManiniMA, IavaroneM, The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010;59:638–644. 10.1136/gut.2009.187286)| false
SchellhaasB, WildnerD, PfeiferL, et al.LI-RADS-CEUS - proposal for a contrast-enhanced ultrasound algorithm for the diagnosis of hepatocellular carcinoma in high-risk populations. Ultraschall Med2016;37(S 01):627–634.
SchellhaasB, WildnerD, PfeiferL, LI-RADS-CEUS - proposal for a contrast-enhanced ultrasound algorithm for the diagnosis of hepatocellular carcinoma in high-risk populations. Ultraschall Med 2016;37(S 01):627–634. 10.1055/s-0036-1587712)| false
ChangTT, SawhneyR, MontoA, et al.Implementation of a multidisciplinary treatment team for hepatocellular cancer at a Veterans Affairs Medical Center improves survival. HPB (Oxford)2008;10:405–411.
ChangTT, SawhneyR, MontoA, Implementation of a multidisciplinary treatment team for hepatocellular cancer at a Veterans Affairs Medical Center improves survival. HPB (Oxford) 2008;10:405–411. 10.1080/13651820802356572)| false
YoppAC, MansourJC, BegMS, et al.Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome. Ann Surg Oncol2014;21:1287–1295.
YoppAC, MansourJC, BegMS, Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome. Ann Surg Oncol 2014;21:1287–1295. 2431809510.1245/s10434-013-3413-8)| false
AgarwalPD, PhillipsP, HillmanL, et al.Multidisciplinary management of hepatocellular carcinoma improves access to therapy and patient survival. J Clin Gastroenterol2017;51:845–849.
SerperM, TaddeiTH, MehtaR, et al.Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality. Gastroenterology2017;152:1954–1964.
SerperM, TaddeiTH, MehtaR, Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality. Gastroenterology 2017;152:1954–1964. 2828342110.1053/j.gastro.2017.02.040)| false
FarinatiF, MarinoD, De GiorgioM, et al.Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?Am J Gastroenterol2006;101:524–532.
FarinatiF, MarinoD, De GiorgioM, Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?Am J Gastroenterol 2006;101:524–532. 10.1111/j.1572-0241.2006.00443.x16542289)| false
TrevisaniF, D’IntinoPE, Morselli-LabateAM, et al.Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol2001;34:570–575.
TrevisaniF, D’IntinoPE, Morselli-LabateAM, Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001;34:570–575. 1139465710.1016/S0168-8278(00)00053-2)| false
TorzilliG, MinagawaM, TakayamaT, Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy. Hepatology 1999;30:889–893. 1049863910.1002/hep.510300411)| false
LokAS, LaiCL.alpha-fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology1989;9:110–115.
LokAS, LaiCL.alpha-fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology 1989;9:110–115. 246189010.1002/hep.1840090119)| false
JohnsonPJ, PirrieSJ, CoxTF, et al.The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomarkers Prev2014;23:144–153.
JohnsonPJ, PirrieSJ, CoxTF, The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomarkers Prev 2014;23:144–153. 10.1158/1055-9965.EPI-13-087024220911)| false
BerhaneS, ToyodaH, TadaT, et al.Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients. Clin Gastroenterol Hepatol2016;14:875–886.e6.
BerhaneS, ToyodaH, TadaT, Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients. Clin Gastroenterol Hepatol 2016;14:875–886.e6. 2677502510.1016/j.cgh.2015.12.042)| false
YangJD, AddissieBD, MaraKC, et al.GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score. Cancer Epidemiol Biomarkers Prev2019;28:531–538.
YangJD, AddissieBD, MaraKC, GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score. Cancer Epidemiol Biomarkers Prev 2019;28:531–538. 10.1158/1055-9965.EPI-18-028130464023)| false
BestJ, BechmannLP, SowaJP, et al.GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol2020;18:728–735.e4.
BestJ, BechmannLP, SowaJP, GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2020;18:728–735.e4. 10.1016/j.cgh.2019.11.012)| false
PomfretEA, WashburnK, WaldC, et al.Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl2010;16:262–278.
PomfretEA, WashburnK, WaldC, Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010;16:262–278. 2020964110.1002/lt.21999)| false
HardingJJ, Abu-ZeinahG, ChouJF, et al.Frequency, morbidity, and mortality of bone metastases in advanced hepatocellular carcinoma. J Natl Compr Canc Netw2018;16:50–58.
CooperGS, BellamyP, DawsonNV, A prognostic model for patients with end-stage liver disease. Gastroenterology 1997;113:1278–1288. 932252310.1053/gast.1997.v113.pm9322523)| false
BruixJ, CastellsA, BoschJ, et al.Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology1996;111:1018–1022.
JohnsonPJ, BerhaneS, KagebayashiC, et al.Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol2015;33:550–558.
JohnsonPJ, BerhaneS, KagebayashiC, Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 2015;33:550–558. 2551245310.1200/JCO.2014.57.9151)| false
OikonomouT, GoulisL, DoumtsisP, et al.ALBI and PALBI grades are associated with the outcome of patients with stable decompensated cirrhosis. Ann Hepatol2019;18:126–136.
OikonomouT, GoulisL, DoumtsisP, ALBI and PALBI grades are associated with the outcome of patients with stable decompensated cirrhosis. Ann Hepatol 2019;18:126–136. 3111358110.5604/01.3001.0012.7904)| false
WanSZ, NieY, ZhangY, et al.Assessing the prognostic performance of the Child-Pugh, Model for End-Stage Liver Disease, and albumin-bilirubin scores in patients with decompensated cirrhosis: a large Asian cohort from gastroenterology department. Dis Markers2020;2020:5193028.
WanSZ, NieY, ZhangY, Assessing the prognostic performance of the Child-Pugh, Model for End-Stage Liver Disease, and albumin-bilirubin scores in patients with decompensated cirrhosis: a large Asian cohort from gastroenterology department. Dis Markers 2020;2020:5193028. 3214856610.1155/2020/5193028)| false
KamathPS, WiesnerRH, MalinchocM, A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464–470. 10.1053/jhep.2001.22172)| false
MalinchocM, KamathPS, GordonFD, et al.A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology2000;31:864–871.
MalinchocM, KamathPS, GordonFD, A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000;31:864–871. 10.1053/he.2000.5852)| false
MartinAP, BartelsM, HaussJ, Overview of the MELD score and the UNOS adult liver allocation system. Transplant Proc 2007;39:3169–3174. 1808934510.1016/j.transproceed.2007.04.025)| false
CholongitasE, PapatheodoridisGV, VangeliM, et al.Systematic review: the model for end-stage liver disease--should it replace Child-Pugh’s classification for assessing prognosis in cirrhosis?Aliment Pharmacol Ther2005;22:1079–1089.
CholongitasE, PapatheodoridisGV, VangeliM, Systematic review: the model for end-stage liver disease--should it replace Child-Pugh’s classification for assessing prognosis in cirrhosis?Aliment Pharmacol Ther 2005;22:1079–1089. 10.1111/j.1365-2036.2005.02691.x16305721)| false
BruixJ, ShermanM, LlovetJM, et al.Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol2001;35:421–430.
DohmenK.Many staging systems for hepatocellular carcinoma: evolution from Child-Pugh, Okuda to SLiDe. J Gastroenterol Hepatol 2004;19:1227–1232. 1548252710.1111/j.1440-1746.2004.03538.x)| false
MarreroJA, FontanaRJ, BarratA, et al.Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology2005;41:707–716.
MarreroJA, FontanaRJ, BarratA, Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005;41:707–716. 10.1002/hep.20636)| false
PawlikTM, PoonRT, AbdallaEK, et al.Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg2005;140:450–457., discussion 457–458.
PawlikTM, PoonRT, AbdallaEK, Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 2005;140:450–457., discussion 457–458. 1589744010.1001/archsurg.140.5.450)| false
ChokKS, NgKK, PoonRT, et al.Impact of postoperative complications on long-term outcome of curative resection for hepatocellular carcinoma. Br J Surg2009;96:81–87.
KianmaneshR, RegimbeauJM, BelghitiJ.Selective approach to major hepatic resection for hepatocellular carcinoma in chronic liver disease. Surg Oncol Clin N Am2003;12:51–63.
KianmaneshR, RegimbeauJM, BelghitiJ.Selective approach to major hepatic resection for hepatocellular carcinoma in chronic liver disease. Surg Oncol Clin N Am 2003;12:51–63. 1273512910.1016/S1055-3207(02)00090-X)| false
LlovetJM, FusterJ, BruixJ.Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology1999;30:1434–1440.
LlovetJM, FusterJ, BruixJ.Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30:1434–1440. 1057352210.1002/hep.510300629)| false
PoonRT-P, FanST, LoCM, et al.Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg2002;235:373–382.
PoonRT-P, FanST, LoCM, Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 2002;235:373–382. 1188275910.1097/00000658-200203000-00009)| false
SeoDD, LeeHC, JangMK, et al.Preoperative portal vein embolization and surgical resection in patients with hepatocellular carcinoma and small future liver remnant volume: comparison with transarterial chemoembolization. Ann Surg Oncol2007;14:3501–3509.
SeoDD, LeeHC, JangMK, Preoperative portal vein embolization and surgical resection in patients with hepatocellular carcinoma and small future liver remnant volume: comparison with transarterial chemoembolization. Ann Surg Oncol 2007;14:3501–3509. 10.1245/s10434-007-9553-y17899289)| false
WeiAC, Tung-Ping PoonR, FanST, et al.Risk factors for perioperative morbidity and mortality after extended hepatectomy for hepatocellular carcinoma. Br J Surg2003;90:33–41.
FaberW, StockmannM, SchirmerC, et al.Significant impact of patient age on outcome after liver resection for HCC in cirrhosis. Eur J Surg Oncol2014;40:208–213.
FaberW, StockmannM, SchirmerC, Significant impact of patient age on outcome after liver resection for HCC in cirrhosis. Eur J Surg Oncol 2014;40:208–213. 2427520210.1016/j.ejso.2013.10.018)| false
RiberoD, CurleySA, ImamuraH, et al.Selection for resection of hepatocellular carcinoma and surgical strategy: indications for resection, evaluation of liver function, portal vein embolization, and resection. Ann Surg Oncol2008;15:986–992.
RiberoD, CurleySA, ImamuraH, Selection for resection of hepatocellular carcinoma and surgical strategy: indications for resection, evaluation of liver function, portal vein embolization, and resection. Ann Surg Oncol 2008;15:986–992. 10.1245/s10434-007-9731-y18236112)| false
BerzigottiA, ReigM, AbraldesJG, et al.Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology2015;61:526–536.
BerzigottiA, ReigM, AbraldesJG, Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology 2015;61:526–536. 10.1002/hep.2743125212123)| false
SantambrogioR, KlugerMD, CostaM, et al.Hepatic resection for hepatocellular carcinoma in patients with Child-Pugh’s A cirrhosis: is clinical evidence of portal hypertension a contraindication?HPB (Oxford)2013;15:78–84.
SantambrogioR, KlugerMD, CostaM, Hepatic resection for hepatocellular carcinoma in patients with Child-Pugh’s A cirrhosis: is clinical evidence of portal hypertension a contraindication?HPB (Oxford) 2013;15:78–84. 10.1111/j.1477-2574.2012.00594.x)| false
TsaiTJ, ChauGY, LuiWY, et al.Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgery2000;127:603–608.
TsaiTJ, ChauGY, LuiWY, Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgery 2000;127:603–608. 1084035310.1067/msy.2000.105498)| false
AbdallaEK, DenysA, HasegawaK, Treatment of large and advanced hepatocellular carcinoma. Ann Surg Oncol 2008;15:979–985. 1823611510.1245/s10434-007-9727-7)| false
JonasS, BechsteinWO, SteinmüllerT, et al.Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology2001;33:1080–1086.
KubotaK, MakuuchiM, KusakaK, et al.Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology1997;26:1176–1181.
KubotaK, MakuuchiM, KusakaK, Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology 1997;26:1176–1181.9362359)| false
KishiY, AbdallaEK, ChunYS, et al.Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry. Ann Surg2009;250:540–548.
KishiY, AbdallaEK, ChunYS, Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry. Ann Surg 2009;250:540–548. 10.1097/SLA.0b013e3181b674df19730239)| false
GlantzounisGK, TokidisE, BasourakosSP, et al.The role of portal vein embolization in the surgical management of primary hepatobiliary cancers. A systematic review. Eur J Surg Oncol2017;43:32–41.
GlantzounisGK, TokidisE, BasourakosSP, The role of portal vein embolization in the surgical management of primary hepatobiliary cancers. A systematic review. Eur J Surg Oncol 2017;43:32–41. 2728389210.1016/j.ejso.2016.05.026)| false
SchlagPM, SennH-J, eds. Methods to improve resectability of hepatocellular carcinoma. In: Recent Results in Cancer Research, Vol. 190. Springer2013:pp. 57-.
SchlagPM, SennH-J, eds. Methods to improve resectability of hepatocellular carcinoma. In: Recent Results in Cancer Research, Vol. 190. Springer2013:pp. 57-.)| false
ChapelleT, Op de BeeckB, RoeyenG, et al.Measuring future liver remnant function prior to hepatectomy may guide the indication for portal vein occlusion and avoid posthepatectomy liver failure: a prospective interventional study. HPB (Oxford)2017;19:108–117.
ChapelleT, Op de BeeckB, RoeyenG, Measuring future liver remnant function prior to hepatectomy may guide the indication for portal vein occlusion and avoid posthepatectomy liver failure: a prospective interventional study. HPB (Oxford) 2017;19:108–117. 10.1016/j.hpb.2016.11.005)| false
MartelG, CieslakKP, HuangR, et al.Comparison of techniques for volumetric analysis of the future liver remnant: implications for major hepatic resections. HPB (Oxford)2015;17:1051–1057.
MartelG, CieslakKP, HuangR, Comparison of techniques for volumetric analysis of the future liver remnant: implications for major hepatic resections. HPB (Oxford) 2015;17:1051–1057. 10.1111/hpb.12480)| false
WattKD, PedersenRA, KremersWK, et al.Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant2010;10:1420–1427.
WattKD, PedersenRA, KremersWK, Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant 2010;10:1420–1427. 10.1111/j.1600-6143.2010.03126.x20486907)| false
MazzaferroV, RegaliaE, DociR, et al.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med1996;334:693–699.
MazzaferroV, RegaliaE, DociR, Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693–699. 10.1056/NEJM1996031433411048594428)| false
VolkML, VijanS, MarreroJA.A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant2008;8:839–846.
VolkML, VijanS, MarreroJA.A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant 2008;8:839–846. 1831878310.1111/j.1600-6143.2007.02138.x)| false
DuffyJP, VardanianA, BenjaminE, et al.Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg2007;246:502–509., discussion 509–511.
DuffyJP, VardanianA, BenjaminE, Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007;246:502–509., discussion 509–511. 1771745410.1097/SLA.0b013e318148c704)| false
YaoFY, FerrellL, BassNM, et al.Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology2001;33:1394–1403.
YaoFY, FerrellL, BassNM, Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394–1403. 10.1053/jhep.2001.24563)| false
YaoFY, BassNM, NikolaiB, et al.Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl2002;8:873–883.
YaoFY, BassNM, NikolaiB, Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002;8:873–883. 10.1053/jlts.2002.34923)| false
KimJ, KoME, NelsonRA, et al.Increasing age and survival after orthotopic liver transplantation for patients with hepatocellular cancer. J Am Coll Surg2014;218:431–438.
KimJ, KoME, NelsonRA, Increasing age and survival after orthotopic liver transplantation for patients with hepatocellular cancer. J Am Coll Surg 2014;218:431–438. 10.1016/j.jamcollsurg.2013.12.00124559955)| false
KozyrevaON, ChiD, ClarkJW, et al.A multicenter retrospective study on clinical characteristics, treatment patterns, and outcome in elderly patients with hepatocellular carcinoma. Oncologist2011;16:310–318.
KozyrevaON, ChiD, ClarkJW, A multicenter retrospective study on clinical characteristics, treatment patterns, and outcome in elderly patients with hepatocellular carcinoma. Oncologist 2011;16:310–318. 2134994810.1634/theoncologist.2010-0223)| false
KwonJH, YoonYI, SongGW, et al.Living donor liver transplantation for patients older than age 70 years: A single-center experience. Am J Transplant2017;17:2890–2900.
KwonJH, YoonYI, SongGW, Living donor liver transplantation for patients older than age 70 years: A single-center experience. Am J Transplant 2017;17:2890–2900. 2851034110.1111/ajt.14355)| false
DolnikovS, AdamR, CherquiD, Liver transplantation in elderly patients: what do we know at the beginning of 2020?Surg Today 2020;50:533–539. 10.1007/s00595-020-01996-732279191)| false
FujikiM, AucejoF, KimR.General overview of neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: necessity or option?Liver Int2011;31:1081–1089.
FujikiM, AucejoF, KimR.General overview of neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: necessity or option?Liver Int 2011;31:1081–1089. 10.1111/j.1478-3231.2011.02473.x)| false
LlovetJM, Di BisceglieAM, BruixJ, Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698–711. 1847780210.1093/jnci/djn134)| false
MajnoP, GiostraE, MenthaG.Management of hepatocellular carcinoma on the waiting list before liver transplantation: time for controlled trials?Liver Transpl2007; 13(11, Suppl 2)S27–S35.
MajnoP, GiostraE, MenthaG.Management of hepatocellular carcinoma on the waiting list before liver transplantation: time for controlled trials?Liver Transpl 2007; 13(11, Suppl 2)S27–S35. 10.1002/lt.2132817969086)| false
PompiliM, MiranteVG, RondinaraG, et al.Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl2005;11:1117–1126.
PompiliM, MiranteVG, RondinaraG, Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl 2005;11:1117–1126. 10.1002/lt.2046916123960)| false
MazzaferroV, BattistonC, PerroneS, et al.Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg2004;240:900–909.
MazzaferroV, BattistonC, PerroneS, Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 2004;240:900–909. 10.1097/01.sla.0000143301.56154.9515492574)| false
YaoFY, BassNM, NikolaiB, et al.A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl2003;9:684–692.
YaoFY, BassNM, NikolaiB, A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl 2003;9:684–692. 1282755310.1053/jlts.2003.50147)| false
DuBayDA, SandroussiC, KachuraJR, et al.Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. HPB (Oxford)2011;13:24–32.
DuBayDA, SandroussiC, KachuraJR, Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. HPB (Oxford) 2011;13:24–32. 10.1111/j.1477-2574.2010.00228.x)| false
TsochatzisE, GarcovichM, MarelliL, et al.Transarterial embolization as neo-adjuvant therapy pretransplantation in patients with hepatocellular carcinoma. Liver Int2013;33:944–949.
TsochatzisE, GarcovichM, MarelliL, Transarterial embolization as neo-adjuvant therapy pretransplantation in patients with hepatocellular carcinoma. Liver Int 2013;33:944–949. 10.1111/liv.1214423530918)| false
RichardHMIII, SilberzweigJE, MittyHA, et al.Hepatic arterial complications in liver transplant recipients treated with pretransplantation chemoembolization for hepatocellular carcinoma. Radiology2000;214:775–779.
GraziadeiIW, SandmuellerH, WaldenbergerP, et al.Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl2003;9:557–563.
GraziadeiIW, SandmuellerH, WaldenbergerP, Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003;9:557–563. 10.1053/jlts.2003.5010612783395)| false
HayashiPH, LudkowskiM, FormanLM, et al.Hepatic artery chemoembolization for hepatocellular carcinoma in patients listed for liver transplantation. Am J Transplant2004;4:782–787.
NicoliniD, Svegliati-BaroniG, CandelariR, et al.Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation. World J Gastroenterol2013;19:5622–5632.
KulikLM, AtassiB, van HolsbeeckL, et al.Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol2006;94:572–586.
SandroussiC, DawsonLA, LeeM, Radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma. Transpl Int 2010;23:299–306. 10.1111/j.1432-2277.2009.00980.x19843294)| false
LuL, ZengJ, WenZ, et al.Transcatheter arterial chemoembolisation followed by three-dimensional conformal radiotherapy versus transcatheter arterial chemoembolisation alone for primary hepatocellular carcinoma in adults. Cochrane Database Syst Rev2019;2:CD012244.
TosoC, MenthaG, KnetemanNM, The place of downstaging for hepatocellular carcinoma. J Hepatol 2010;52:930–936. 2038542810.1016/j.jhep.2009.12.032)| false
YaoFY, FidelmanN.Reassessing the boundaries of liver transplantation for hepatocellular carcinoma: Where do we stand with tumor down-staging?Hepatology2016;63:1014–1025.
YaoFY, FidelmanN.Reassessing the boundaries of liver transplantation for hepatocellular carcinoma: Where do we stand with tumor down-staging?Hepatology 2016;63:1014–1025. 2656049110.1002/hep.28139)| false
KulikL, HeimbachJK, ZaiemF, et al.Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis. Hepatology2018;67:381–400.
LivraghiT, GoldbergSN, LazzaroniS, et al.Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology1999;210:655–661.
LencioniRA, AllgaierHP, CioniD, et al.Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology2003;228:235–240.
LinS-M, LinC-J, LinC-C, et al.Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology2004;127:1714–1723.
LinSM, LinCJ, LinCC, et al.Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut2005;54:1151–1156.
ShiinaS, TerataniT, ObiS, et al.A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology2005;129:122–130.
ShiinaS, TerataniT, ObiS, A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005;129:122–130. 1601294210.1053/j.gastro.2005.04.009)| false
BrunelloF, VeltriA, CarucciP, et al.Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial. Scand J Gastroenterol2008;43:727–735.
GiorgioA, Di SarnoA, De StefanoG, et al.Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Res2011;31:2291–2295.
GiorgioA, Di SarnoA, De StefanoG, Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Res 2011;31:2291–2295.21737654)| false
WeisS, FrankeA, MössnerJ, et al.Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma. Cochrane Database Syst Rev2013;12:CD003046.
WeisS, FrankeA, MössnerJ, Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma. Cochrane Database Syst Rev 2013;12:CD003046. )| false
HuangG-T, LeeP-H, TsangY-M, et al.Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. Ann Surg2005;242:36–42.
HuangG-T, LeeP-H, TsangY-M, Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. Ann Surg 2005;242:36–42. 1597309910.1097/01.sla.0000167925.90380.fe)| false
ChenM-S, LiJ-Q, ZhengY, et al.A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg2006;243:321–328.
ChenM-S, LiJ-Q, ZhengY, A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006;243:321–328. 1649569510.1097/01.sla.0000201480.65519.b8)| false
HuangJ, YanL, ChengZ, et al.A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg2010;252:903–912.
HuangJ, YanL, ChengZ, A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 2010;252:903–912. 10.1097/SLA.0b013e3181efc656)| false
FengK, YanJ, LiX, et al.A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol2012;57:794–802.
FengK, YanJ, LiX, A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 2012;57:794–802. 10.1016/j.jhep.2012.05.00722634125)| false
FangY, ChenW, LiangX, et al.Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma. J Gastroenterol Hepatol2014;29:193–200.
FangY, ChenW, LiangX, Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma. J Gastroenterol Hepatol 2014;29:193–200. 2422477910.1111/jgh.12441)| false
NgKKC, ChokKSH, ChanACY, et al.Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma. Br J Surg2017;104:1775–1784.
FengQ, ChiY, LiuY, et al.Efficacy and safety of percutaneous radiofrequency ablation versus surgical resection for small hepatocellular carcinoma: a meta-analysis of 23 studies. J Cancer Res Clin Oncol2015;141:1–9.
FengQ, ChiY, LiuY, Efficacy and safety of percutaneous radiofrequency ablation versus surgical resection for small hepatocellular carcinoma: a meta-analysis of 23 studies. J Cancer Res Clin Oncol 2015;141:1–9. 10.1007/s00432-014-1708-124889505)| false
JiaJB, ZhangD, LudwigJM, et al.Radiofrequency ablation versus resection for hepatocellular carcinoma in patients with Child-Pugh A liver cirrhosis: a meta-analysis. Clin Radiol2017;72:1066–1075.
JiaJB, ZhangD, LudwigJM, Radiofrequency ablation versus resection for hepatocellular carcinoma in patients with Child-Pugh A liver cirrhosis: a meta-analysis. Clin Radiol 2017;72:1066–1075. 2885149110.1016/j.crad.2017.07.024)| false
XuG, QiF-Z, ZhangJ-H, et al.Meta-analysis of surgical resection and radiofrequency ablation for early hepatocellular carcinoma. World J Surg Oncol2012;10:163–163.
XuG, QiF-Z, ZhangJ-H, Meta-analysis of surgical resection and radiofrequency ablation for early hepatocellular carcinoma. World J Surg Oncol 2012;10:163–163. 2289781510.1186/1477-7819-10-163)| false
CaiH, KongW, ZhouT, et al.Radiofrequency ablation versus reresection in treating recurrent hepatocellular carcinoma: a meta-analysis. Medicine (Baltimore)2014;93:e122.
CaiH, KongW, ZhouT, Radiofrequency ablation versus reresection in treating recurrent hepatocellular carcinoma: a meta-analysis. Medicine (Baltimore) 2014;93:e122. 10.1097/MD.0000000000000122)| false
DingJ, JingX, LiuJ, Comparison of two different thermal techniques for the treatment of hepatocellular carcinoma. Eur J Radiol 2013;82:1379–1384. 10.1016/j.ejrad.2013.04.02523726122)| false
GroeschlRT, PilgrimCHC, HannaEM, Microwave ablation for hepatic malignancies: a multiinstitutional analysis. Ann Surg 2013;259:1195–1200.10.1097/SLA.0000000000000234)| false
ZhangL, WangN, ShenQ, et al.Therapeutic efficacy of percutaneous radiofrequency ablation versus microwave ablation for hepatocellular carcinoma. PLoS One2013;8:e76119.
ZhangL, WangN, ShenQ, Therapeutic efficacy of percutaneous radiofrequency ablation versus microwave ablation for hepatocellular carcinoma. PLoS One 2013;8:e76119. 10.1371/journal.pone.007611924146824)| false
ShiJ, SunQ, WangY, et al.Comparison of microwave ablation and surgical resection for treatment of hepatocellular carcinomas conforming to Milan criteria. J Gastroenterol Hepatol2014;29:1500–1507.
ShiJ, SunQ, WangY, Comparison of microwave ablation and surgical resection for treatment of hepatocellular carcinomas conforming to Milan criteria. J Gastroenterol Hepatol 2014;29:1500–1507. 10.1111/jgh.1257224628534)| false
SchefferHJ, NielsenK, de JongMC, et al.Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. J Vasc Interv Radiol2014;25:997–1011., quiz 1011.
SchefferHJ, NielsenK, de JongMC, Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. J Vasc Interv Radiol 2014;25:997–1011., quiz 1011. 10.1016/j.jvir.2014.01.02824656178)| false
CheungW, KavnoudiasH, RobertsS, et al.Irreversible electroporation for unresectable hepatocellular carcinoma: initial experience and review of safety and outcomes. Technol Cancer Res Treat2013;12:233–241.
CheungW, KavnoudiasH, RobertsS, Irreversible electroporation for unresectable hepatocellular carcinoma: initial experience and review of safety and outcomes. Technol Cancer Res Treat 2013;12:233–241. 2336915210.7785/tcrt.2012.500317)| false
CannonR, EllisS, HayesD, et al.Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol2013;107:544–549.
CannonR, EllisS, HayesD, Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol 2013;107:544–549. 2309072010.1002/jso.23280)| false
FrühlingP, NilssonA, DurajF, et al.Single-center nonrandomized clinical trial to assess the safety and efficacy of irreversible electroporation (IRE) ablation of liver tumors in humans: Short to mid-term results. Eur J Surg Oncol2017;43:751–757.
FrühlingP, NilssonA, DurajF, Single-center nonrandomized clinical trial to assess the safety and efficacy of irreversible electroporation (IRE) ablation of liver tumors in humans: Short to mid-term results. Eur J Surg Oncol 2017;43:751–757. 2810967410.1016/j.ejso.2016.12.004)| false
RandT, LoeweC, SchoderM, et al.Arterial embolization of unresectable hepatocellular carcinoma with use of microspheres, lipiodol, and cyanoacrylate. Cardiovasc Intervent Radiol2005;28:313–318.
RandT, LoeweC, SchoderM, Arterial embolization of unresectable hepatocellular carcinoma with use of microspheres, lipiodol, and cyanoacrylate. Cardiovasc Intervent Radiol 2005;28:313–318. 1588694310.1007/s00270-004-0153-y)| false
HuangYH, ChenCH, ChangTT, et al.The role of transcatheter arterial embolization for patients with unresectable hepatocellular carcinoma: a nationwide, multicentre study evaluated by cancer stage. Aliment Pharmacol Ther2005;21:687–694.
HuangYH, ChenCH, ChangTT, The role of transcatheter arterial embolization for patients with unresectable hepatocellular carcinoma: a nationwide, multicentre study evaluated by cancer stage. Aliment Pharmacol Ther 2005;21:687–694. 10.1111/j.1365-2036.2005.02404.x15771754)| false
MaluccioMA, CoveyAM, PoratLB, et al.Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol2008;19:862–869.
MaluccioMA, CoveyAM, PoratLB, Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2008;19:862–869. 1850390010.1016/j.jvir.2008.02.013)| false
BonomoG, PediciniV, MonfardiniL, et al.Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up. Cardiovasc Intervent Radiol2010;33:552–559.
BonomoG, PediciniV, MonfardiniL, Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up. Cardiovasc Intervent Radiol 2010;33:552–559. 10.1007/s00270-009-9752-y19957182)| false
LlovetJM, RealMI, MontañaX, et al.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet2002;359:1734–1739.
LlovetJM, RealMI, MontañaX, Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734–1739. 10.1016/S0140-6736(02)08649-X12049862)| false
KongJY, LiSM, FanHY, et al.Transarterial chemoembolization extends long-term survival in patients with unresectable hepatocellular carcinoma. Medicine (Baltimore)2018;97:e11872.
BrownKT, DoRK, GonenM, et al.Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol2016;34:2046–2053.
PoonRT, TsoWK, PangRW, et al.A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol2007;5:1100–1108.
PoonRT, TsoWK, PangRW, A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 2007;5:1100–1108. 1762790210.1016/j.cgh.2007.04.021)| false
ReyesDK, VossenJA, KamelIR, et al.Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J2009;15:526–532.
ReyesDK, VossenJA, KamelIR, Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J 2009;15:526–532. 2001017310.1097/PPO.0b013e3181c5214b)| false
LammerJ, MalagariK, VoglT, et al.Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol2010;33:41–52.
LammerJ, MalagariK, VoglT, Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010;33:41–52. 1990809310.1007/s00270-009-9711-7)| false
MalagariK, PomoniM, KelekisA, et al.Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol2010;33:541–551.
MalagariK, PomoniM, KelekisA, Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010;33:541–551. 10.1007/s00270-009-9750-019937027)| false
DhanasekaranR, KoobyDA, StaleyCA, et al.Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol2010;101:476–480.
SongMJ, ChunHJ, SongDS, et al.Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol2012;57:1244–1250.
SongMJ, ChunHJ, SongDS, Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 2012;57:1244–1250. 10.1016/j.jhep.2012.07.01722824821)| false
GolfieriR, GiampalmaE, RenzulliM, et al.Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer2014;111:255–264.
YangB, LiangJ, QuZ, et al.Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: A systematic review. PLoS One2020;15:e0227475.
YangB, LiangJ, QuZ, Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: A systematic review. PLoS One 2020;15:e0227475. 3207410210.1371/journal.pone.0227475)| false
LiapiE, GeschwindJ-FH.Intra-arterial therapies for hepatocellular carcinoma: where do we stand?Ann Surg Oncol 2010;17:1234–1246. 2040532810.1245/s10434-010-0977-4)| false
IbrahimSM, LewandowskiRJ, SatoKT, et al.Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol2008;14:1664–1669.
IbrahimSM, LewandowskiRJ, SatoKT, Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol 2008;14:1664–1669. 1835059710.3748/wjg.14.1664)| false
KulikLM, CarrBI, MulcahyMF, et al.Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology2008;47:71–81.
KulikLM, CarrBI, MulcahyMF, Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008;47:71–81. 1802788410.1002/hep.21980)| false
WoodallCE, ScogginsCR, EllisSF, et al.Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis?J Am Coll Surg2009;208:375–382.
WoodallCE, ScogginsCR, EllisSF, Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis?J Am Coll Surg 2009;208:375–382. 1931799910.1016/j.jamcollsurg.2008.12.009)| false
SalemR, LewandowskiRJ, MulcahyMF, et al.Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology2010;138:52–64.
SalemR, LewandowskiRJ, MulcahyMF, Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010;138:52–64. 1976663910.1053/j.gastro.2009.09.006)| false
SangroB, CarpaneseL, CianniR, et al.Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology2011;54:868–878.
SangroB, CarpaneseL, CianniR, Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011;54:868–878. 10.1002/hep.2445121618574)| false
MazzaferroV, SpositoC, BhooriS, et al.Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology2013;57:1826–1837.
VoucheM, HabibA, WardTJ, et al.Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology2014;60:192–201.
GarinE, TselikasL, GuiuB, et al.Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol2021;6:17–29.
VilgrainV, PereiraH, AssenatE, et al.Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol2017;18:1624–1636.
ChowPKH, GandhiM, TanSB, et al.SIRveNIB: Selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol2018;36:1913–1921.
HawkinsMA, DawsonLA.Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer 2006;106:1653–1663. 10.1002/cncr.2181116541431)| false
HoffeSE, FinkelsteinSE, RussellMS, et al.Nonsurgical options for hepatocellular carcinoma: evolving role of external beam radiotherapy. Cancer Contr2010;17:100–110.
HoffeSE, FinkelsteinSE, RussellMS, Nonsurgical options for hepatocellular carcinoma: evolving role of external beam radiotherapy. Cancer Contr 2010;17:100–110. 10.1177/107327481001700205)| false
KwonJH, BaeSH, KimJY, et al.Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer2010;10:475–475.
KwonJH, BaeSH, KimJY, Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer 2010;10:475–475. 10.1186/1471-2407-10-475)| false
AndolinoDL, JohnsonCS, MaluccioM, et al.Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys2011;81:e447–e453.
HuangW-Y, JenY-M, LeeM-S, et al.Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. Int J Radiat Oncol Biol Phys2012;84:355–361.
KangJ-K, KimM-S, ChoCK, et al.Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer2012;118:5424–5431.
KangJ-K, KimM-S, ChoCK, Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer 2012;118:5424–5431. 2257017910.1002/cncr.27533)| false
BujoldA, MasseyCA, KimJJ, et al.Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol2013;31:1631–1639.
BujoldA, MasseyCA, KimJJ, Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 2013;31:1631–1639. 10.1200/JCO.2012.44.165923547075)| false
CárdenesHR, PriceTR, PerkinsSM, et al.Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol2010;12:218–225.
WahlDR, StenmarkMH, TaoY, et al.Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol2016;34:452–459.
WahlDR, StenmarkMH, TaoY, Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol 2016;34:452–459. 10.1200/JCO.2015.61.4925)| false
VelecM, HaddadCR, CraigT, et al.Predictors of liver toxicity following stereotactic body radiation therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys2017;97:939–946.
VelecM, HaddadCR, CraigT, Predictors of liver toxicity following stereotactic body radiation therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2017;97:939–946. 10.1016/j.ijrobp.2017.01.22128333016)| false
TseRV, HawkinsM, LockwoodG, et al.Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol2008;26:657–664.
TseRV, HawkinsM, LockwoodG, Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008;26:657–664. 1817218710.1200/JCO.2007.14.3529)| false
LlovetJM, VilanaR, BrúC, et al.Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology2001;33:1124–1129.
LlovetJM, VilanaR, BrúC, Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 2001;33:1124–1129. 10.1053/jhep.2001.2423311343240)| false
LivraghiT, SolbiatiL, MeloniMF, et al.Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology2003;226:441–451.
LencioniR, CioniD, CrocettiL, et al.Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology2005;234:961–967.
ZhangY-J, LiangH-H, ChenM-S, et al.Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial. Radiology2007;244:599–607.
ZhangY-J, LiangH-H, ChenM-S, Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial. Radiology 2007;244:599–607. 10.1148/radiol.2442060826)| false
